Anti eotaxin-2 antibodies attenuate the initiation and progression of experimental atherosclerosisReport as inadecuate




Anti eotaxin-2 antibodies attenuate the initiation and progression of experimental atherosclerosis - Download this document for free, or read online. Document in PDF available to download.

Background: The chemokine eotaxin-2 is a potent chemoattractant for inflammatory cells, the predominants of which are eosinophils. Human and murine atherosclerotic plaques are known to exhibit inflammatory phenotypes where a complex interaction of cytokine and chemokines plays a role. We tested the hypothesis that eotaxin-2 eo-2 plays a causative role in the initiation and progression of experimental atherosclerosis. Methods and Results: Sera collected from atherosclerotic ApoE knockout KO mice, exhibited significantly higher levels of eo-2 compared to sera collected from their background age matched C57BL-6 litters by ELISA. Moreover, levels of eo-2 were higher in old atherosclerotic ApoE KO mice than in young animals. Similarly, the expression level of the eo-2 receptor, CCR3, was increased in splenocytes of old ApoE compared to the young littermates. Administration of polyclonal blocking antibodies to eotaxin-2 resulted in a significant reduction of early atherosclerotic plaques in ApoE KO mice whereas prolonged treatment of mice with advanced plaques led to atheroma stabilization. A monoclonal antibody D8 prepared against eo-2 attenuated adhesion of lymphocytes to fibronectin and potently inhibited their migration towards VEGF. Monoclonal blocking antibodies to eo-2 also significantly reduced atherosclerotic plaques in ApoE KO mice. Conclusion: Eo-2 serum levels are elevated in sera of ApoE KO mice with experimental atherosclerosis and its blockade is associated with reduced fatty streak accumulation and increased plaque stabilization.

KEYWORDS

Atherosclerosis; Vulnerable Plaque; Inflammation; Eotaxin-2; Chemokines

Cite this paper

Mor, A. , Afek, A. , Entin-Meer, M. , Keren, G. and George, J. 2013 Anti eotaxin-2 antibodies attenuate the initiation and progression of experimental atherosclerosis. World Journal of Cardiovascular Diseases, 3, 339-346. doi: 10.4236-wjcd.2013.34054.





Author: Adi Mor, Arnon Afek, Michal Entin-Meer, Gad Keren, Jacob George

Source: http://www.scirp.org/



DOWNLOAD PDF




Related documents